🟢 NeoGenomics is trading 4.22% up in pre-market after raising 2026 revenue and adjusted EBITDA guidance

NeoGenomics is trading 4.22% up at $18.75 in pre-market on October 29, following its third-quarter results and raised 2026 outlook, announced after the market closed on October 28.

• Revenue was $209 million; NeoGenomics raised full-year revenue guidance to $807–$809 million and adjusted EBITDA guidance to approximately $60 million.
• NGS revenue grew 29% year over year, while adjusted EBITDA rose 53%.
• Healthcare stocks were higher pre-market, while major U.S. indices were lower.